[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55093A - Méthodes et compositions pour le traitement du cancer - Google Patents

Méthodes et compositions pour le traitement du cancer

Info

Publication number
MA55093A
MA55093A MA055093A MA55093A MA55093A MA 55093 A MA55093 A MA 55093A MA 055093 A MA055093 A MA 055093A MA 55093 A MA55093 A MA 55093A MA 55093 A MA55093 A MA 55093A
Authority
MA
Morocco
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
MA055093A
Other languages
English (en)
Inventor
Graeme Currie
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of MA55093A publication Critical patent/MA55093A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA055093A 2019-03-01 2020-03-03 Méthodes et compositions pour le traitement du cancer MA55093A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812929P 2019-03-01 2019-03-01
US201962856216P 2019-06-03 2019-06-03
US201962907504P 2019-09-27 2019-09-27

Publications (1)

Publication Number Publication Date
MA55093A true MA55093A (fr) 2022-01-05

Family

ID=72235995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055093A MA55093A (fr) 2019-03-01 2020-03-03 Méthodes et compositions pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20200277387A1 (fr)
EP (1) EP3930705A4 (fr)
AU (1) AU2020232695A1 (fr)
IL (1) IL285796A (fr)
MA (1) MA55093A (fr)
MX (1) MX2021010449A (fr)
SG (1) SG11202109336UA (fr)
WO (1) WO2020180898A1 (fr)
ZA (1) ZA202107139B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345909B (es) 2009-03-25 2017-02-22 Genentech Inc Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2022092085A1 (fr) * 2020-10-28 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition pharmaceutique pour le traitement de tumeurs
WO2024104922A1 (fr) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Procédé d'amélioration de la fonction musculaire squelettique
WO2024194300A1 (fr) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Méthode de traitement d'une déformation thoraco-lombaire chez un sujet humain atteint d'achondroplasie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345909B (es) * 2009-03-25 2017-02-22 Genentech Inc Anticuerpos anti-fgfr3 y métodos que los utilizan.
AU2016219917B2 (en) * 2015-02-19 2021-12-16 Fusion Pharmaceuticals Inc. Methods, compositions, and kits for treatment of cancer
SG11201906249PA (en) * 2017-02-06 2019-08-27 Rainier Therapeutics Inc Methods, compositions, and kits for treatment of cancer

Also Published As

Publication number Publication date
ZA202107139B (en) 2024-03-27
EP3930705A4 (fr) 2023-09-06
IL285796A (en) 2021-10-31
WO2020180898A8 (fr) 2020-10-29
EP3930705A1 (fr) 2022-01-05
AU2020232695A1 (en) 2021-10-28
SG11202109336UA (en) 2021-09-29
WO2020180898A1 (fr) 2020-09-10
US20200277387A1 (en) 2020-09-03
MX2021010449A (es) 2021-09-21

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3983445A4 (fr) Compositions et méthodes de traitement du cancer
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3870104A4 (fr) Méthodes et substances pour le traitement du cancer
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP4138869A4 (fr) Compositions et méthodes comprenant clostridium butrycum pour le traitement du cancer
EP3373951A4 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
MA52499A (fr) Associations pour le traitement du cancer
EP3519592A4 (fr) Matières et méthodes pour l'évaluation et le traitement du cancer
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer